康泰生物(300601.SZ)：终止与阿斯利康设立合资公司

Core Viewpoint - The company announced the termination of the investment agreement to establish a joint venture with AstraZeneca due to significant market changes and high risks in the vaccine industry [1] Group 1: Joint Venture Details - The company planned to establish a joint venture with AstraZeneca focusing on vaccines, with a registered capital of 345 million RMB (approximately 50 million USD) [1] - Both the company and AstraZeneca were to hold 50% equity in the joint venture, with a total investment estimated at around 400 million USD (approximately 2.76 billion RMB) [1] Group 2: Termination of Agreement - The decision to terminate the investment agreement was made after careful evaluation and friendly negotiations among the parties involved [1] - The termination was approved in a board meeting held on February 6, 2026, and the company management was authorized to finalize and sign the relevant termination agreements [1]